z-logo
Premium
Evaluation of methemoglobin as an autologous intravascular MRI contrast agent
Author(s) -
Duewell Stefan,
Kasserra Claudia E.,
Jezzard Peter,
Balaban Robert S.
Publication year - 1996
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1910350521
Subject(s) - methemoglobin , in vivo , bolus (digestion) , hemoglobin , nuclear magnetic resonance , chemistry , magnetic resonance imaging , medicine , radiology , biochemistry , physics , microbiology and biotechnology , biology
Methemoglobin (MetHb) was evaluated as an intravascular paramagnetic contrast agent. Methemoglobin formation was induced by 4‐dimethylaminophenol (4‐DMAP), causing a reduction in blood T 2 * in vitro. The 4‐DMAP generated metHb with a time constant of 62 s. A 4‐DMAP bolus did not decrease measurably the signal intensity in the in vivo rabbit kidney in the first pass. At steady state, a MetHb concentration of 24.8 ± 2.3% resulted in a signal decrease of 9.2 ± 2.6% in the kidney. Methemoglobin is an effective vascular T 2 * relaxation agent, but the formation of MetHb by 4‐DMAP is too slow for first‐pass imaging. A more effective conversion agent resulting in a bolus of at least 25% MetHb within 5 s would result in a detectable first‐pass signal and a viable contrast technique.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom